Login to Your Account



Corcept, FDA Reach Accord On Depression Drug Studies

By Randall Osborne


Tuesday, August 31, 2004
Four months after going public on the strength of its GR-II receptor antagonists, Corcept Therapeutics Inc. reached agreement on a special protocol assessment for pivotal Phase III trials to test its lead product Corlux (mifepristone) against the psychotic features of major depression. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription